FindTrial
Sign In

Long-term phase III study in patients with chronic pain.

Long-term study of HFT-290 in patients with chronic pain.

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221311
Enrollment
Unknown
Registered
2010-11-16
Start date
2010-11-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic pain

Interventions

investigational material(s) Generic name etc : HFT-290 (fentanyl citrate patch) INN of investigational material : Therapeutic category code : 821 Synthetic narcotics Dosage and Administration for Inv

Sponsors

Hisamitsu Pharmaceutical Co., Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Patients with chronic pain persisting for at least 12 weeks before obtaining informed consent

Exclusion criteria

Exclusion criteria: - Patients with abnormalities at the site of application - Patients in whom the primary cause of chronic pain (the target of evaluation) is considered to be persistent somatoform pain disorder - Patients who are scheduled to undergo an operation with a potential influence on the evaluation of pain for at least 7 days before starting administration of the investigational drug

Design outcomes

Primary

MeasureTime frame
efficacy, safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026